参考文献：
[1] 何莉.高同型半胱氨酸血症与高血压病发病机制的研究进展[D].2015.
[2] 中华医学会内分泌学分会. 原发性醛固酮增多症诊断治疗的专家共识 (2020 版)[J]. 中华内分泌代谢杂志, 2020, 36(9): 727-736.
[3] 于蕾,胡滨,吴洁,李倩倩,陈宝荣.同时测定血浆血管紧张素Ⅰ、Ⅱ和醛固酮的液相色谱 串联质谱法的建立与评价[J].临床检验杂志,2022,(04):251-256
[4] Satoh F, Morimoto R, Ono Y, et al. 8d. 02: Peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in primary aldosteronism patients[J]. Journal of Hypertension, 2015, 33: e113.
[5] 高寅洁, 谢绍伟, 刘世颖, 等. LC-MS/MS 检测类固醇激素谱在诊断原发性醛固酮增多症中的应用[J]. 基础医学与临床, 2022, 42(12): 1835.
[6] Zhao B, Bian J, Rao M, et al. A dilute‐and‐shoot liquid chromatography–tandem mass spectrometry method for urinary 18‐hydroxycortisol quantification and its application in establishing reference intervals[J]. Journal of Clinical Laboratory Analysis, 2022, 36(8): e24580.
[7] 胡嘉禄, 崔兆强, 葛均波. 嗜铬细胞瘤和副神经节瘤的诊断与临床管理[J]. 中华高血压杂志, 2020, 28(2): 179-186.
[8] 中华医学会内分泌学分会.嗜铬细胞瘤和副神经节瘤诊断治疗专家共识(2020版)[J].中华内分泌代谢杂志, 2020, 36(09):737-750.
[9] FLESERIU M，AUCHUS R，BANCOS I，et al. Consensus on diagnosis and management of Cushing’s disease：a guideline update［J］. Lancet Diabetes Endocrinol，2021，9（12）：847- 875.
[10] Janeiro M H, Ramírez M J, Milagro F I, et al. Implication of trimethylamine N-oxide (TMAO) in disease: potential biomarker or new therapeutic target[J]. Nutrients, 2018, 10(10): 1398.
[11] Wang Z, Tang W H W, Buffa J A, et al. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide[J]. European heart journal, 2014, 35(14): 904-910.
[12] Tang W H W, Wang Z, Fan Y, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis[J]. Journal of the American College of Cardiology, 2014, 64(18): 1908-1914.
[13] Heianza Y, Ma W, Manson J A E, et al. Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: a systematic review and meta‐analysis of prospective studies[J]. Journal of the American Heart Association, 2017, 6(7): e004947.
[14] Schiattarella G G, Sannino A, Toscano E, et al. Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis[J]. European heart journal, 2017, 38(39): 2948-2956.
[15] 王康, 杨慧宇, 智丽霞. 神经酰胺在心血管疾病中的研究进展 [J] . 中国医师杂志, 2022, 24(5) : 793-797.
LI Q, WANG X, PANG J, et al. Associations between plasma ceramides and mortality in patients with coronary artery disease[J]. Atherosclerosis, 2020, 314: 77-83.
[16] Hilvo M, Vasile V C, Donato L J, et al. Ceramides and ceramide scores: clinical applications for cardiometabolic risk stratification[J]. Frontiers in endocrinology, 2020, 11: 570628.
[17] Hilvo Mika,Meikle Peter J,Pedersen Eva Ringdal et al. Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients.[J] .Eur Heart J, 2020, 41: 371-380.
